![John Patrick Genn](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
John Patrick Genn
Nessuna posizione attualmente
Relazioni attive
Nome | Sesso | Età | Società collegate | Collaborazione |
---|---|---|---|---|
James Caruso | M | 65 | 9 anni | |
Stefan Loren | M | 60 | 9 anni | |
Larry E. Rittenberg | M | 78 |
University of Wisconsin
| 48 anni |
Grafico relazionale
Relazione in diverse aziende
Relazioni precedenti
Nome | Sesso | Età | Società collegate | Collaborazione |
---|---|---|---|---|
Simon Pedder | M | 63 |
Novelos Therapeutics, Inc.
![]() Novelos Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Novelos Therapeutics, Inc. is a pharmaceutical company, which is engaged in the development of novel drugs for the treatment and diagnosis of cancer. It comprises of three cancer-targeted compounds: GLOW2, HOT and LIGHT, which are used for the treatment of cancer. Its therapeutic compounds directly kill cancer cells while minimizing harm to normal cells. This offers the potential for a paradigm shift in cancer therapy by providing efficacy in all three major drivers of mortality in cancer: primary tumors, metastases and stem cell-based relapse. Its LIGHT compound is a small-molecule cancer-targeted imaging agent, which is potential for selective detection of tumors and metastases in a broad range of cancers. Its HOT compound is a small-molecule, broad-spectrum, cancer-targeted molecular radio therapeutic that delivers radiation directly and selectively to cancer cells and cancer stem cells. Its GLOW2 compound is a small-molecule, broad-spectrum, cancer-targeted, non-radioactive optical imaging agent which is potential for intraoperative tumor margin illumination and non-invasive tumor imaging. The company was founded on June 21, 1996 and is headquartered in Madison, WI. | 2 anni |
Kathryn M. McNeil | F | 49 |
Novelos Therapeutics, Inc.
![]() Novelos Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Novelos Therapeutics, Inc. is a pharmaceutical company, which is engaged in the development of novel drugs for the treatment and diagnosis of cancer. It comprises of three cancer-targeted compounds: GLOW2, HOT and LIGHT, which are used for the treatment of cancer. Its therapeutic compounds directly kill cancer cells while minimizing harm to normal cells. This offers the potential for a paradigm shift in cancer therapy by providing efficacy in all three major drivers of mortality in cancer: primary tumors, metastases and stem cell-based relapse. Its LIGHT compound is a small-molecule cancer-targeted imaging agent, which is potential for selective detection of tumors and metastases in a broad range of cancers. Its HOT compound is a small-molecule, broad-spectrum, cancer-targeted molecular radio therapeutic that delivers radiation directly and selectively to cancer cells and cancer stem cells. Its GLOW2 compound is a small-molecule, broad-spectrum, cancer-targeted, non-radioactive optical imaging agent which is potential for intraoperative tumor margin illumination and non-invasive tumor imaging. The company was founded on June 21, 1996 and is headquartered in Madison, WI. | 2 anni |
Paul Berns | M | 57 |
Novelos Therapeutics, Inc.
![]() Novelos Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Novelos Therapeutics, Inc. is a pharmaceutical company, which is engaged in the development of novel drugs for the treatment and diagnosis of cancer. It comprises of three cancer-targeted compounds: GLOW2, HOT and LIGHT, which are used for the treatment of cancer. Its therapeutic compounds directly kill cancer cells while minimizing harm to normal cells. This offers the potential for a paradigm shift in cancer therapy by providing efficacy in all three major drivers of mortality in cancer: primary tumors, metastases and stem cell-based relapse. Its LIGHT compound is a small-molecule cancer-targeted imaging agent, which is potential for selective detection of tumors and metastases in a broad range of cancers. Its HOT compound is a small-molecule, broad-spectrum, cancer-targeted molecular radio therapeutic that delivers radiation directly and selectively to cancer cells and cancer stem cells. Its GLOW2 compound is a small-molecule, broad-spectrum, cancer-targeted, non-radioactive optical imaging agent which is potential for intraoperative tumor margin illumination and non-invasive tumor imaging. The company was founded on June 21, 1996 and is headquartered in Madison, WI. | 3 anni |
Harry Palmin | M | 54 |
Novelos Therapeutics, Inc.
![]() Novelos Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Novelos Therapeutics, Inc. is a pharmaceutical company, which is engaged in the development of novel drugs for the treatment and diagnosis of cancer. It comprises of three cancer-targeted compounds: GLOW2, HOT and LIGHT, which are used for the treatment of cancer. Its therapeutic compounds directly kill cancer cells while minimizing harm to normal cells. This offers the potential for a paradigm shift in cancer therapy by providing efficacy in all three major drivers of mortality in cancer: primary tumors, metastases and stem cell-based relapse. Its LIGHT compound is a small-molecule cancer-targeted imaging agent, which is potential for selective detection of tumors and metastases in a broad range of cancers. Its HOT compound is a small-molecule, broad-spectrum, cancer-targeted molecular radio therapeutic that delivers radiation directly and selectively to cancer cells and cancer stem cells. Its GLOW2 compound is a small-molecule, broad-spectrum, cancer-targeted, non-radioactive optical imaging agent which is potential for intraoperative tumor margin illumination and non-invasive tumor imaging. The company was founded on June 21, 1996 and is headquartered in Madison, WI. | 15 anni |
Ed Bohórquez | M | 77 |
University of Wisconsin
| 5 anni |
George Michael Douglas | M | - |
University of Wisconsin
| 6 anni |
Joanne M. Protano | F | 55 |
Novelos Therapeutics, Inc.
![]() Novelos Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Novelos Therapeutics, Inc. is a pharmaceutical company, which is engaged in the development of novel drugs for the treatment and diagnosis of cancer. It comprises of three cancer-targeted compounds: GLOW2, HOT and LIGHT, which are used for the treatment of cancer. Its therapeutic compounds directly kill cancer cells while minimizing harm to normal cells. This offers the potential for a paradigm shift in cancer therapy by providing efficacy in all three major drivers of mortality in cancer: primary tumors, metastases and stem cell-based relapse. Its LIGHT compound is a small-molecule cancer-targeted imaging agent, which is potential for selective detection of tumors and metastases in a broad range of cancers. Its HOT compound is a small-molecule, broad-spectrum, cancer-targeted molecular radio therapeutic that delivers radiation directly and selectively to cancer cells and cancer stem cells. Its GLOW2 compound is a small-molecule, broad-spectrum, cancer-targeted, non-radioactive optical imaging agent which is potential for intraoperative tumor margin illumination and non-invasive tumor imaging. The company was founded on June 21, 1996 and is headquartered in Madison, WI. | 8 anni |
Chad Kolean | M | 59 | 3 anni | |
James Manuso | M | 75 |
Novelos Therapeutics, Inc.
![]() Novelos Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Novelos Therapeutics, Inc. is a pharmaceutical company, which is engaged in the development of novel drugs for the treatment and diagnosis of cancer. It comprises of three cancer-targeted compounds: GLOW2, HOT and LIGHT, which are used for the treatment of cancer. Its therapeutic compounds directly kill cancer cells while minimizing harm to normal cells. This offers the potential for a paradigm shift in cancer therapy by providing efficacy in all three major drivers of mortality in cancer: primary tumors, metastases and stem cell-based relapse. Its LIGHT compound is a small-molecule cancer-targeted imaging agent, which is potential for selective detection of tumors and metastases in a broad range of cancers. Its HOT compound is a small-molecule, broad-spectrum, cancer-targeted molecular radio therapeutic that delivers radiation directly and selectively to cancer cells and cancer stem cells. Its GLOW2 compound is a small-molecule, broad-spectrum, cancer-targeted, non-radioactive optical imaging agent which is potential for intraoperative tumor margin illumination and non-invasive tumor imaging. The company was founded on June 21, 1996 and is headquartered in Madison, WI. | 7 anni |
Lars Christian Pallesen | M | 76 |
University of Wisconsin
| 4 anni |
Donald A. Johnson | M | - |
University of Wisconsin
| 11 anni |
Thomas Ng | M | - |
University of Wisconsin
| 10 anni |
Bernard Dion | M | - |
University of Wisconsin
| 4 anni |
Michael B. Zemel | M | - |
University of Wisconsin
| 8 anni |
Raymond Hirsch | M | 76 |
University of Wisconsin
| 12 anni |
Jim Tatera | M | - |
University of Wisconsin
| 2 anni |
Howard M. Schneider | M | 80 |
Novelos Therapeutics, Inc.
![]() Novelos Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Novelos Therapeutics, Inc. is a pharmaceutical company, which is engaged in the development of novel drugs for the treatment and diagnosis of cancer. It comprises of three cancer-targeted compounds: GLOW2, HOT and LIGHT, which are used for the treatment of cancer. Its therapeutic compounds directly kill cancer cells while minimizing harm to normal cells. This offers the potential for a paradigm shift in cancer therapy by providing efficacy in all three major drivers of mortality in cancer: primary tumors, metastases and stem cell-based relapse. Its LIGHT compound is a small-molecule cancer-targeted imaging agent, which is potential for selective detection of tumors and metastases in a broad range of cancers. Its HOT compound is a small-molecule, broad-spectrum, cancer-targeted molecular radio therapeutic that delivers radiation directly and selectively to cancer cells and cancer stem cells. Its GLOW2 compound is a small-molecule, broad-spectrum, cancer-targeted, non-radioactive optical imaging agent which is potential for intraoperative tumor margin illumination and non-invasive tumor imaging. The company was founded on June 21, 1996 and is headquartered in Madison, WI. | 9 anni |
Christopher J. Pazoles | M | 73 |
Novelos Therapeutics, Inc.
![]() Novelos Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Novelos Therapeutics, Inc. is a pharmaceutical company, which is engaged in the development of novel drugs for the treatment and diagnosis of cancer. It comprises of three cancer-targeted compounds: GLOW2, HOT and LIGHT, which are used for the treatment of cancer. Its therapeutic compounds directly kill cancer cells while minimizing harm to normal cells. This offers the potential for a paradigm shift in cancer therapy by providing efficacy in all three major drivers of mortality in cancer: primary tumors, metastases and stem cell-based relapse. Its LIGHT compound is a small-molecule cancer-targeted imaging agent, which is potential for selective detection of tumors and metastases in a broad range of cancers. Its HOT compound is a small-molecule, broad-spectrum, cancer-targeted molecular radio therapeutic that delivers radiation directly and selectively to cancer cells and cancer stem cells. Its GLOW2 compound is a small-molecule, broad-spectrum, cancer-targeted, non-radioactive optical imaging agent which is potential for intraoperative tumor margin illumination and non-invasive tumor imaging. The company was founded on June 21, 1996 and is headquartered in Madison, WI. | 9 anni |
Khalid Hamad Al-Yahya | M | 65 |
University of Wisconsin
| 5 anni |
Mark W. Neumann | M | - |
University of Wisconsin
| 6 anni |
John R. Depies | M | - |
University of Wisconsin
| 7 anni |
Thomas Mackie | M | 69 |
Novelos Therapeutics, Inc.
![]() Novelos Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Novelos Therapeutics, Inc. is a pharmaceutical company, which is engaged in the development of novel drugs for the treatment and diagnosis of cancer. It comprises of three cancer-targeted compounds: GLOW2, HOT and LIGHT, which are used for the treatment of cancer. Its therapeutic compounds directly kill cancer cells while minimizing harm to normal cells. This offers the potential for a paradigm shift in cancer therapy by providing efficacy in all three major drivers of mortality in cancer: primary tumors, metastases and stem cell-based relapse. Its LIGHT compound is a small-molecule cancer-targeted imaging agent, which is potential for selective detection of tumors and metastases in a broad range of cancers. Its HOT compound is a small-molecule, broad-spectrum, cancer-targeted molecular radio therapeutic that delivers radiation directly and selectively to cancer cells and cancer stem cells. Its GLOW2 compound is a small-molecule, broad-spectrum, cancer-targeted, non-radioactive optical imaging agent which is potential for intraoperative tumor margin illumination and non-invasive tumor imaging. The company was founded on June 21, 1996 and is headquartered in Madison, WI. | 3 anni |
Bruce D. Neviaser | M | - |
Continuum Investment LP
![]() Continuum Investment LP Investment ManagersFinance Continuum Investment LP (Continuum Investment) is a venture capital firm founded in 2005 by Bruce D Neviaser. The firm is headquartered in Middleton, Wisconsin. | 18 anni |
Jeffrey E. Thompson | M | - |
University of Wisconsin
| 8 anni |
Jamey P. Weichert | M | 67 |
Novelos Therapeutics, Inc.
![]() Novelos Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Novelos Therapeutics, Inc. is a pharmaceutical company, which is engaged in the development of novel drugs for the treatment and diagnosis of cancer. It comprises of three cancer-targeted compounds: GLOW2, HOT and LIGHT, which are used for the treatment of cancer. Its therapeutic compounds directly kill cancer cells while minimizing harm to normal cells. This offers the potential for a paradigm shift in cancer therapy by providing efficacy in all three major drivers of mortality in cancer: primary tumors, metastases and stem cell-based relapse. Its LIGHT compound is a small-molecule cancer-targeted imaging agent, which is potential for selective detection of tumors and metastases in a broad range of cancers. Its HOT compound is a small-molecule, broad-spectrum, cancer-targeted molecular radio therapeutic that delivers radiation directly and selectively to cancer cells and cancer stem cells. Its GLOW2 compound is a small-molecule, broad-spectrum, cancer-targeted, non-radioactive optical imaging agent which is potential for intraoperative tumor margin illumination and non-invasive tumor imaging. The company was founded on June 21, 1996 and is headquartered in Madison, WI. | 3 anni |
Glenn H. Isensee | M | - |
University of Wisconsin
| 8 anni |
L. J. Nickisch | M | - |
University of Wisconsin
| 5 anni |
John E. Carlson | M | - |
University of Wisconsin
| 5 anni |
Robert J. Karnauskas | M | - |
University of Wisconsin
| 6 anni |
Albert R. Zimmerli | M | 72 |
University of Wisconsin
| 5 anni |
Ann M. Murphy | F | - |
University of Wisconsin
| 7 anni |
Steven T. Berman | M | 61 |
University of Wisconsin
| 7 anni |
Philip J. Ziegler | M | - |
University of Wisconsin
| 6 anni |
Pete Brey | M | 69 |
University of Wisconsin
| 4 anni |
Yu Neng Lim | M | 61 |
University of Wisconsin
| 5 anni |
Steve Alley | M | 71 |
University of Wisconsin
| 5 anni |
Tim J. Sheehan | M | - |
University of Wisconsin
| 6 anni |
John Niederhuber | M | 85 |
Novelos Therapeutics, Inc.
![]() Novelos Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Novelos Therapeutics, Inc. is a pharmaceutical company, which is engaged in the development of novel drugs for the treatment and diagnosis of cancer. It comprises of three cancer-targeted compounds: GLOW2, HOT and LIGHT, which are used for the treatment of cancer. Its therapeutic compounds directly kill cancer cells while minimizing harm to normal cells. This offers the potential for a paradigm shift in cancer therapy by providing efficacy in all three major drivers of mortality in cancer: primary tumors, metastases and stem cell-based relapse. Its LIGHT compound is a small-molecule cancer-targeted imaging agent, which is potential for selective detection of tumors and metastases in a broad range of cancers. Its HOT compound is a small-molecule, broad-spectrum, cancer-targeted molecular radio therapeutic that delivers radiation directly and selectively to cancer cells and cancer stem cells. Its GLOW2 compound is a small-molecule, broad-spectrum, cancer-targeted, non-radioactive optical imaging agent which is potential for intraoperative tumor margin illumination and non-invasive tumor imaging. The company was founded on June 21, 1996 and is headquartered in Madison, WI. | 3 anni |
Mark Keeling | M | - |
University of Wisconsin
| 6 anni |
Daniel Robert Chappie | M | - |
University of Wisconsin
| 4 anni |
Barrett L. Browning | M | - |
University of Wisconsin
| 8 anni |
Stephen Hill | M | 65 |
Novelos Therapeutics, Inc.
![]() Novelos Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Novelos Therapeutics, Inc. is a pharmaceutical company, which is engaged in the development of novel drugs for the treatment and diagnosis of cancer. It comprises of three cancer-targeted compounds: GLOW2, HOT and LIGHT, which are used for the treatment of cancer. Its therapeutic compounds directly kill cancer cells while minimizing harm to normal cells. This offers the potential for a paradigm shift in cancer therapy by providing efficacy in all three major drivers of mortality in cancer: primary tumors, metastases and stem cell-based relapse. Its LIGHT compound is a small-molecule cancer-targeted imaging agent, which is potential for selective detection of tumors and metastases in a broad range of cancers. Its HOT compound is a small-molecule, broad-spectrum, cancer-targeted molecular radio therapeutic that delivers radiation directly and selectively to cancer cells and cancer stem cells. Its GLOW2 compound is a small-molecule, broad-spectrum, cancer-targeted, non-radioactive optical imaging agent which is potential for intraoperative tumor margin illumination and non-invasive tumor imaging. The company was founded on June 21, 1996 and is headquartered in Madison, WI. | 7 anni |
Jay Robert Sekelsky | M | 65 |
University of Wisconsin
| 6 anni |
Rick Lane | M | - |
University of Wisconsin
| 7 anni |
Tom Stevens | M | - |
University of Wisconsin
| 6 anni |
Kenneth Hanson Crawford | M | - |
University of Wisconsin
| 5 anni |
Boon San Gan | M | 62 |
University of Wisconsin
| 5 anni |
Stephen Petersen | M | 68 |
University of Wisconsin
| 5 anni |
John Neis | M | 68 |
Novelos Therapeutics, Inc.
![]() Novelos Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Novelos Therapeutics, Inc. is a pharmaceutical company, which is engaged in the development of novel drugs for the treatment and diagnosis of cancer. It comprises of three cancer-targeted compounds: GLOW2, HOT and LIGHT, which are used for the treatment of cancer. Its therapeutic compounds directly kill cancer cells while minimizing harm to normal cells. This offers the potential for a paradigm shift in cancer therapy by providing efficacy in all three major drivers of mortality in cancer: primary tumors, metastases and stem cell-based relapse. Its LIGHT compound is a small-molecule cancer-targeted imaging agent, which is potential for selective detection of tumors and metastases in a broad range of cancers. Its HOT compound is a small-molecule, broad-spectrum, cancer-targeted molecular radio therapeutic that delivers radiation directly and selectively to cancer cells and cancer stem cells. Its GLOW2 compound is a small-molecule, broad-spectrum, cancer-targeted, non-radioactive optical imaging agent which is potential for intraoperative tumor margin illumination and non-invasive tumor imaging. The company was founded on June 21, 1996 and is headquartered in Madison, WI. | 3 anni |
Thomas C. Goesch | M | - |
University of Wisconsin
| 7 anni |
William Harvey | M | 75 |
University of Wisconsin
| 7 anni |
Michael A. Austin | M | - |
University of Wisconsin
| 6 anni |
John Harold Underwood | M | - |
University of Wisconsin
| 5 anni |
David R. Semmel | M | - |
University of Wisconsin
| 4 anni |
David Lesar | M | 70 |
University of Wisconsin
| 7 anni |
Jan Janick | M | 65 |
University of Wisconsin
| - |
James B. Boyd | M | 71 |
University of Wisconsin
| 6 anni |
Marilyn Holt-Smith | F | - |
University of Wisconsin
| 7 anni |
Phill Gross | M | - |
University of Wisconsin
| 5 anni |
Mike Reckmeyer | M | - |
University of Wisconsin
| 7 anni |
Brian Gary Rafn | M | - |
University of Wisconsin
| 6 anni |
Gregory H. Sachs | M | 59 |
University of Wisconsin
| 7 anni |
Kevin Kozak | M | - |
Novelos Therapeutics, Inc.
![]() Novelos Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Novelos Therapeutics, Inc. is a pharmaceutical company, which is engaged in the development of novel drugs for the treatment and diagnosis of cancer. It comprises of three cancer-targeted compounds: GLOW2, HOT and LIGHT, which are used for the treatment of cancer. Its therapeutic compounds directly kill cancer cells while minimizing harm to normal cells. This offers the potential for a paradigm shift in cancer therapy by providing efficacy in all three major drivers of mortality in cancer: primary tumors, metastases and stem cell-based relapse. Its LIGHT compound is a small-molecule cancer-targeted imaging agent, which is potential for selective detection of tumors and metastases in a broad range of cancers. Its HOT compound is a small-molecule, broad-spectrum, cancer-targeted molecular radio therapeutic that delivers radiation directly and selectively to cancer cells and cancer stem cells. Its GLOW2 compound is a small-molecule, broad-spectrum, cancer-targeted, non-radioactive optical imaging agent which is potential for intraoperative tumor margin illumination and non-invasive tumor imaging. The company was founded on June 21, 1996 and is headquartered in Madison, WI. | 1 anni |
Stuart Michael Rossmiller | M | - |
University of Wisconsin
| 9 anni |
Catherine Leslie Witeck | F | - |
University of Wisconsin
| 6 anni |
Tom Frisbie | M | 72 |
University of Wisconsin
| 6 anni |
Mark Richard Mirsberger | M | - |
University of Wisconsin
| 6 anni |
William Schultz | M | - |
University of Wisconsin
| 6 anni |
Jerome R. Baier | M | - |
University of Wisconsin
| 5 anni |
Brian K. Yeazel | M | - |
University of Wisconsin
| 6 anni |
Robert Piepenburg | M | - |
University of Wisconsin
| 6 anni |
Tevfik Özakat | M | 68 |
University of Wisconsin
| 6 anni |
Michael F. Tweedle | M | 73 |
Novelos Therapeutics, Inc.
![]() Novelos Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Novelos Therapeutics, Inc. is a pharmaceutical company, which is engaged in the development of novel drugs for the treatment and diagnosis of cancer. It comprises of three cancer-targeted compounds: GLOW2, HOT and LIGHT, which are used for the treatment of cancer. Its therapeutic compounds directly kill cancer cells while minimizing harm to normal cells. This offers the potential for a paradigm shift in cancer therapy by providing efficacy in all three major drivers of mortality in cancer: primary tumors, metastases and stem cell-based relapse. Its LIGHT compound is a small-molecule cancer-targeted imaging agent, which is potential for selective detection of tumors and metastases in a broad range of cancers. Its HOT compound is a small-molecule, broad-spectrum, cancer-targeted molecular radio therapeutic that delivers radiation directly and selectively to cancer cells and cancer stem cells. Its GLOW2 compound is a small-molecule, broad-spectrum, cancer-targeted, non-radioactive optical imaging agent which is potential for intraoperative tumor margin illumination and non-invasive tumor imaging. The company was founded on June 21, 1996 and is headquartered in Madison, WI. | 3 anni |
Mike M. Gerdes | M | - |
University of Wisconsin
| 4 anni |
Norman Doll | M | - |
University of Wisconsin
| 4 anni |
Jeffrey A. Horn | M | 68 |
University of Wisconsin
| 4 anni |
Michael Pepke | M | - |
University of Wisconsin
| 4 anni |
David Lyle Warnock | M | 66 |
University of Wisconsin
| 2 anni |
Edward Akin Leigh | M | - |
University of Wisconsin
| 2 anni |
Dan Larson | M | - |
University of Wisconsin
| 5 anni |
Diane L. Ford | F | 70 |
University of Wisconsin
| 2 anni |
Christopher J. Hornung | M | 72 |
University of Wisconsin
| 4 anni |
David Grandin | M | 62 |
University of Wisconsin
| 4 anni |
Jeffrey Thomas May | M | - |
University of Wisconsin
| 4 anni |
Mike Flesch | M | 66 |
University of Wisconsin
| 4 anni |
Russell Last | M | - |
University of Wisconsin
| 6 anni |
Roy Shepard | M | - |
University of Wisconsin
| 2 anni |
Kent E. Willetts | M | - |
University of Wisconsin
| 4 anni |
John F. Syburg | M | - |
University of Wisconsin
| 3 anni |
Gary King | M | - |
University of Wisconsin
| 4 anni |
John C. Wayne | M | 62 |
University of Wisconsin
| 4 anni |
Patricia N. Perry | F | - |
University of Wisconsin
| 4 anni |
Sakir Sömek | M | 61 |
University of Wisconsin
| 4 anni |
Gerald D. Schiefelbein | M | 65 |
University of Wisconsin
| 4 anni |
Richard A. Davies | M | - |
University of Wisconsin
| 5 anni |
Kathy Pederson | F | - |
University of Wisconsin
| 2 anni |
William Reilly | M | 61 |
University of Wisconsin
| 4 anni |
Statistiche
Paese | Relazioni | % del totale |
---|---|---|
Stati Uniti | 100 | 100.00% |
Età delle relazioni
Attive
Scorse
Uomo
Donna
Amministratori
Dirigenti
Provenienza delle relazioni
- Borsa valori
- Insiders
- John Patrick Genn
- Contatti personali